

JC01 Rec'd PCT/ 02 SEP 2005

PTO/SB/21 (08-00)

Please type a plus sign (+) inside this box → ☐

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b> SEP 02 2005 Patent & Trademark Office To be used for all correspondence after initial filing)	Application Number	10/536,927
	Filing Date	May 31, 2005
	First Named Inventor	David Frederick HORROBIN
	Group Art Unit	Not yet assigned
	Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	Attorney Docket Number	56170/316314

## ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 1. Form PTO/SB/08 (one sheet) 2. 7 publications 3. Return Receipt Postcard
<b>Remarks</b>		

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Bruce D. Gray, Reg. No. 35,799
Signature	
Date	August 31, 2005

## CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 2233-1450 on this date:			
Typed or printed name	Gina Hamrick		
Signature	Gina Hamrick	Date	August 31, 2005

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Docket No.: 56170/316314

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: David Frederick HORROBIN (deceased), et al.

Serial No.: 10/536,927                      Group Art Unit: Not yet assigned

Filed: May 31, 2005                      Examiner: Not yet Assigned

For: **TREATMENT OF HUNTINGTON'S DISEASE WITH EPA**

Commissioner for Patents  
P.O. Box 1450  
Alexandria VA, 22313-1450

---

**INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with Rules 56, 97 and 98 of the Rules of Practice in Patent Cases (37 C.F.R. §§ 1.56, 1.97, and 1.98), the publications listed on the modified Form PTO-1449 are enclosed with this submission for consideration by the Examiner.

Submission of the references provided in this Information Disclosure Statement is not intended to constitute an admission that any reference referred to herein is prior art for this invention unless specifically designated as such. Also, in accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that an exhaustive search has been made or that no other material information as defined in 37 C.F.R. § 1.56(a) exists.

In accordance with 37 C.F.R. § 1.98(d), copies of the cited references are not enclosed as they were previously cited in prior application No. 09/835,453 (now allowed), to which the instant application relies upon for an earlier filing date under 35 U.S.C. 120.

U.S.N.: 10/440,802  
Filed: May 19, 2003  
For: Coatings for Metal Casting Parts  
INFORMATION DISCLOSURE STATEMENT

This Information Disclosure Statement is being filed before the issuance of a first office action on the merits of the application (37 C.F.R. 1.97(b)(3)); therefore, no fee is believed to be due. If a fee is due, the Commissioner is authorized to charge such fee and any additional fees that may be due or credit any overpayment to Deposit Account No. 11-0855.

Respectfully submitted,



Bruce D. Gray  
Reg. No. 35,799

Date: August 31, 2005

KILPATRICK STOCKTON LLP  
Suite 2800, 1100 Peachtree Street  
Atlanta, Georgia 30309-4530  
(404) 815-6218

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

SEP 09 2005

(use as many sheets as necessary)

Sheet

1

of

1

**Complete if Known**

Application Number

April 16, 2003

First Named Inventor

Group Art Unit

Examiner Name

Attorney Docket Number

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
		6,384,077	May 7, 2002	Peet, et al.	
		US 2002/0077361 A1	June 20, 2002	Peet, et al.	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
		EP 0 614 977 A2	3/7/1994	The General Hospital Corporation		
		WO 99/15639	4/1/1999	McGill University		
		WO 00/44361	8/3/2000	Laxdale Limited		
		WO 01/24781 A2	4/12/2001	Nova-Neuron Inc.		

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		MARTHA A. NANCE, M.D. "Clinical Aspects of CAG Repeat Diseases," Brain Pathology 7:881-900 (1997)	
		NINA WILLUMSEN, ET AL. "On the effect of 2-deuterium-and 2-methyl- eicosapentaenoic acid derivatives on triglycerides, peroxisomal $\beta$ -oxidation and platelet aggregation in rats," Biochimics et Biophysics Acts 1369 (1998) 193- 203	
		MARK W. BERCHER, ET AL. "Intranuclear Neuronal Inclusion in Huntington's Disease and Dentatorubral and Pallidoluysian Atrophy: Correlation Between the Density of Inclusions and IT15 CAG Triplet Repeat Length," Menrobiology of Disease 4, 387-397 (1998) Article No. NB980168	

Examiner  
Signature

Date

Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.